Skip to main content
TipRanks
Go Ultimate75% OFF

IRLAB Therapeutics AB Class A (IRLAB.A) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

IRLAB Therapeutics AB Class A has a market cap or net worth of SEK 114.36M. The enterprise value is SEK 187.72M.

Market Cap
SEK 114.36M
Enterprise Value
SEK 187.72M

Share Statistics

IRLAB Therapeutics AB Class A has 148,632,140 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
148,632,140
Owned by Insiders
―
Owned by Institutions
―

Financial Efficiency

IRLAB Therapeutics AB Class A’s return on equity (ROE) is -3.58 and return on invested capital (ROIC) is -152.21%.

Return on Equity (ROE)
-3.58
Return on Assets (ROA)
-0.80
Return on Invested Capital (ROIC)
-152.21%
Return on Capital Employed (ROCE)
-3.01
Revenue Per Employee
1.85M
Profits Per Employee
-3.55M
Employee Count
31
Asset Turnover
0.42
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of IRLAB Therapeutics AB Class A is -1.53. IRLAB Therapeutics AB Class A’s PEG ratio is -0.01.

PE Ratio
-1.53
PS Ratio
1.70
PB Ratio
1.37
Price to FCF
-1.48
Price to Operating Cash Flow
-1.42
PEG Ratio
-0.01

Income Statement

In the last 12 months, IRLAB Therapeutics AB Class A had revenue of 57.46M and earned -110.01M in profits. Earnings per share was -1.64.

Revenue
57.46M
Gross Profit
-92.35M
Operating Income
-92.35M
Pretax Income
-110.01M
Net Income
-110.01M
EBITDA
-88.03M
Earnings Per Share (EPS)
-1.64

Cash Flow

In the last 12 months, operating cash flow was -77.27M and capital expenditures 0, giving a free cash flow of -77.27M billion.

Operating Cash Flow
-77.27M
Free Cash Flow
-77.27M
Free Cash Flow per Share
-0.54

Dividends & Yields

IRLAB Therapeutics AB Class A pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-67.60%
Earnings Yield
-42.63%

Stock Price Statistics

Beta
0.42
52-Week Price Change
-65.22%
50-Day Moving Average
1.83
200-Day Moving Average
1.54
Relative Strength Index (RSI)
25.85
Average Volume (3m)
2.79M

Important Dates

IRLAB Therapeutics AB Class A upcoming earnings date is Feb 24, 2027, Before Open (Not Confirmed).

Last Earnings Date
Nov 13, 2026
Next Earnings Date
Feb 24, 2027
Ex-Dividend Date
―

Financial Position

IRLAB Therapeutics AB Class A as a current ratio of 0.80, with Debt / Equity ratio of 97.51%

Current Ratio
0.80
Quick Ratio
0.80
Debt to Market Cap
0.20
Net Debt to EBITDA
0.59
Interest Coverage Ratio
-5.13

Taxes

In the past 12 months, IRLAB Therapeutics AB Class A has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

IRLAB Therapeutics AB Class A EV to EBITDA ratio is -1.05, with an EV/FCF ratio of -0.54.

EV to Sales
0.62
EV to EBITDA
-1.05
EV to Free Cash Flow
-0.54
EV to Operating Cash Flow
-0.54

Balance Sheet

IRLAB Therapeutics AB Class A has SEK 90.64M in cash and marketable securities with SEK 17.93M in debt, giving a net cash position of SEK 72.71M billion.

Cash & Marketable Securities
SEK 90.64M
Total Debt
SEK 17.93M
Net Cash
SEK 72.71M
Net Cash Per Share
SEK 0.49
Tangible Book Value Per Share
SEK 0.23

Margins

Gross margin is -64.85%, with operating margin of -64.85%, and net profit margin of -69.35%.

Gross Margin
-64.85%
Operating Margin
-64.85%
Pretax Margin
-69.35%
Net Profit Margin
-69.35%
EBITDA Margin
-58.73%
EBIT Margin
-64.85%

Analyst Forecast

The average price target for IRLAB Therapeutics AB Class A is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
-21.20%
EPS Growth Forecast
68.24%

Scores

Smart Score
―
AI Score
42